U.S. federal agency Food and Drug Administration (FDA) has approved a multi-regional pilot to study the utilization of Blockchain-optimized data technology to track and authenticate specialty prescription drugs, to ensure safety, improve the value and advance health outcomes. For this multi-regional pilot, the pilot consortium has people from Rymedi, Temptime/Zebra, Indiana University Health, WakeMed Health & Hospitals, Good Shepherd Pharmacy, and its RemediChain project, with the Center for Supply Chain Studies and the Global Health Policy Institute. The group will test the execution of the Drug Supply Chain Security Act (DSCSA) and will begin in August this year.
According to the report, the pilot will focus on intra- and inter-health system medication transport and usage in North Carolina, Indiana, and Tennessee, and studies the application of Blockchain and IoT technology used to monitor specialty medication distribution across supply chains. Ahead of testing the execution of next-gen Blockchain and IoT tech, this pilot advances emerging best-practices for healthcare system data sharing and coordination. With movements toward value-based healthcare and precision medicine advancing in the U.S. and abroad, this connected health infrastructure paves the way for the patient-centric future that healthcare innovators across the globe are working towards. As part of the announcement, the Center for Supply Chain Studies and the Global Health Policy Institute at the University of California San Diego will provide design and assessment support to optimize the pilot’s impact on policy and industry standards development.
Moreover, the Indiana University Health, the largest hospital network in Indiana, and the leading provider of health services in Raleigh, N.C. WakeMed Health & Hospitals will deploy the blockchain solution to track specialty medicines across provider locations within their networks, in addition to transfers to other provider networks, as is commonly done to address regional inventory shortages. As part of the pilot, Good Shepherd Pharmacy and its associated RemediChain project will implement the solution to medicine transfers in their ground-breaking approach to connecting patients who incapable to afford specialty and rare disease medications with donated medications, all while assuring patients, regulators, and providers of the origin and quality of the donated medicines.